KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Boston Scientific (BSX) Accounts Payables (2016 - 2025)

Boston Scientific's Accounts Payables history spans 17 years, with the latest figure at $1.1 billion for Q4 2025.

  • For Q4 2025, Accounts Payables rose 19.17% year-over-year to $1.1 billion; the TTM value through Dec 2025 reached $1.1 billion, up 19.17%, while the annual FY2025 figure was $1.1 billion, 19.17% up from the prior year.
  • Accounts Payables for Q4 2025 was $1.1 billion at Boston Scientific, up from $960.0 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $1.1 billion in Q4 2025 and bottomed at $674.0 million in Q3 2021.
  • The 5-year median for Accounts Payables is $868.0 million (2023), against an average of $863.6 million.
  • The largest annual shift saw Accounts Payables soared 68.87% in 2021 before it rose 1.91% in 2024.
  • A 5-year view of Accounts Payables shows it stood at $794.0 million in 2021, then increased by 8.56% to $862.0 million in 2022, then rose by 9.28% to $942.0 million in 2023, then rose by 1.91% to $960.0 million in 2024, then rose by 19.17% to $1.1 billion in 2025.
  • Per Business Quant, the three most recent readings for BSX's Accounts Payables are $1.1 billion (Q4 2025), $960.0 million (Q4 2024), and $906.0 million (Q2 2024).